The trajectory of the erectile dysfunction drug presents a intricate picture for investors. While the initial introduction generated massive profits, the expiration of its patent opened the floodgates to generic versions, dramatically diminishing knockoff market share. This presents a unique challenge for drug manufacturers banking on related block

The legacy of Viagra, and its creator copyright, presents a intriguing case study for investors. Originally a blockbuster drug, generating billions in income, its intellectual property lapse created a wave of lower-priced alternatives , significantly diminishing its position . While specific firms may attempt to capitalize on similar conditions , t